Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 368

1.

Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group.

Sroussi M, Elaidi R, Fléchon A, Lorcet M, Borchiellini D, Tardy MP, Gravis G, Guérin M, Laguerre B, Estrade F, Delva R, Barthélémy P, Loriot Y, Lavaud P, Lebret T, Neuzillet Y, Penel N, Houede N, Pouessel D, Rousseau B, Mussat E, Gross-Goupil M, Culine S, Gauthier H, Gobert A, Roupret M, Huillard O, Tartas S, Radulescu C, Allory Y, Oudard S.

Clin Genitourin Cancer. 2019 Dec 5. pii: S1558-7673(19)30365-9. doi: 10.1016/j.clgc.2019.11.014. [Epub ahead of print]

PMID:
31882335
2.

EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort: Under the Auspices of the EAU-ESMO Guidelines Committees.

Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Der Kwast TV, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, De Blok W, J L De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, J G Oyen W, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Der Heijden AGV, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A.

Eur Urol. 2020 Feb;77(2):223-250. doi: 10.1016/j.eururo.2019.09.035. Epub 2019 Nov 19.

PMID:
31753752
3.

EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†.

Horwich A, Babjuk M, Bellmunt J, Bruins HM, Reijke TM, Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Kwast TV, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, Bari B, Blok W, De Visschere PJL, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, Oyen WJG, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Witjes JA.

Ann Oncol. 2019 Nov 1;30(11):1697-1727. doi: 10.1093/annonc/mdz296.

PMID:
31740927
4.

Astonishing Evolution in Oropharyngeal Cancer with Immunotherapy: A Case Report.

Rossillon A, Benhamou J, Baccar LS, Hourseau M, Beatrix B, Faivre S, Culine S, Maingon P, Lamuraglia M.

Cancer Invest. 2019;37(10):531-534. doi: 10.1080/07357907.2019.1662032. Epub 2019 Oct 16.

PMID:
31619066
5.

A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors.

Teixeira L, Medioni J, Garibal J, Adotevi O, Doucet L, Durey MD, Ghrieb Z, Kiladjian JJ, Brizard M, Laheurte C, Wehbe M, Pliquet E, Escande M, Defrance R, Culine S, Oudard S, Wain-Hobson S, Doppler V, Huet T, Langlade-Demoyen P.

Clin Cancer Res. 2019 Sep 26. doi: 10.1158/1078-0432.CCR-19-1614. [Epub ahead of print]

PMID:
31558479
6.

[The quality and quantity of life of the elderly person in oncology].

Aregui A, Qabbal R, Culine S, Diaz VF.

Soins Gerontol. 2019 Sep - Oct;24(139):19-21. doi: 10.1016/j.sger.2019.07.004. French.

PMID:
31540716
7.

CD8+PD-1-ILT2+ T Cells Are an Intratumoral Cytotoxic Population Selectively Inhibited by the Immune-Checkpoint HLA-G.

Dumont C, Jacquier A, Verine J, Noel F, Goujon A, Wu CL, Hung TM, Desgrandchamps F, Culine S, Carosella ED, Rouas-Freiss N, LeMaoult J.

Cancer Immunol Res. 2019 Oct;7(10):1619-1632. doi: 10.1158/2326-6066.CIR-18-0764. Epub 2019 Aug 26.

PMID:
31451484
8.

Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.

Landre T, Guetz GD, Chouahnia K, Fossey-Diaz V, Taleb C, Culine S.

Clin Genitourin Cancer. 2019 Aug;17(4):e806-e813. doi: 10.1016/j.clgc.2019.05.001. Epub 2019 May 13.

PMID:
31227430
9.

Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.

Flippot R, Dalban C, Laguerre B, Borchiellini D, Gravis G, Négrier S, Chevreau C, Joly F, Geoffrois L, Ladoire S, Mahammedi H, Rolland F, Gross-Goupil M, Deluche E, Priou F, Laramas M, Barthélémy P, Narciso B, Houedé N, Culine S, Oudard S, Chenot M, Tantot F, Chabaud S, Escudier B, Albiges L.

J Clin Oncol. 2019 Aug 10;37(23):2008-2016. doi: 10.1200/JCO.18.02218. Epub 2019 Jun 13.

PMID:
31194611
10.

Understanding chemotherapy-induced changes in bladder cancer biology: a necessary step towards tailored treatment in cisplatin-refractory disease.

Dumont C, Gauthier H, Bonnet C, Culine S.

Transl Androl Urol. 2019 Mar;8(Suppl 1):S116-S118. doi: 10.21037/tau.2018.12.08. No abstract available.

11.

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.

Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Nam K, Frenkl TL, Perini RF, de Wit R, Bajorin DF.

Ann Oncol. 2019 Jun 1;30(6):970-976. doi: 10.1093/annonc/mdz127.

12.

Prediction of docetaxel toxicity in older cancer patients: a Bayesian network approach.

Khayi F, Lafarge L, Terret C, Albrand G, Falquet B, Culine S, Gourgou S, Ducher M, Bourguignon L.

Fundam Clin Pharmacol. 2019 Dec;33(6):679-686. doi: 10.1111/fcp.12476. Epub 2019 May 29.

PMID:
31038767
13.

Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial.

Oudard S, Latorzeff I, Caty A, Miglianico L, Sevin E, Hardy-Bessard AC, Delva R, Rolland F, Mouret L, Priou F, Beuzeboc P, Gravis G, Linassier C, Gomez P, Voog E, Muracciole X, Abraham C, Banu E, Ferrero JM, Ravaud A, Krakowski I, Lagrange JL, Deplanque G, Zylberait D, Bozec L, Houede N, Culine S, Elaidi R.

JAMA Oncol. 2019 May 1;5(5):623-632. doi: 10.1001/jamaoncol.2018.6607.

PMID:
30703190
14.

Abiraterone in metastatic castration-resistant prostate cancer: Efficacy and safety in unselected patients.

Marret G, Doucet L, Hennequin C, Fizazi K, Culine S.

Cancer Treat Res Commun. 2018;17:37-42. doi: 10.1016/j.ctarc.2018.10.001. Epub 2018 Oct 16.

PMID:
30347333
15.

Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study.

Guillot A, Joly C, Barthélémy P, Meriaux E, Negrier S, Pouessel D, Chevreau C, Mahammedi H, Houede N, Roubaud G, Gravis G, Tartas S, Albiges L, Vassal C, Oriol M, Tinquaut F, Espenel S, Bouleftour W, Culine S, Fizazi K.

Clin Genitourin Cancer. 2019 Feb;17(1):e38-e43. doi: 10.1016/j.clgc.2018.08.006. Epub 2018 Sep 6.

PMID:
30279115
16.

Prediction of non-muscle-invasive bladder cancer recurrence by measurement of checkpoint HLAG's receptor ILT2 on peripheral CD8+ T cells.

Desgrandchamps F, LeMaoult J, Goujon A, Riviere A, Rivero-Juarez A, Djouadou M, de Gouvello A, Dumont C, Wu CL, Culine S, Verine J, Rouas-Freiss N, Hennequin C, Masson-Lecomte A, Carosella ED.

Oncotarget. 2018 Sep 4;9(69):33160-33169. doi: 10.18632/oncotarget.26036. eCollection 2018 Sep 4.

17.

Refining the use of neoadjuvant chemotherapy in locally advanced bladder cancer: from conviction to optimization.

Culine S, Allory Y, Pfister C.

Transl Androl Urol. 2018 Aug;7(4):757-759. doi: 10.21037/tau.2018.06.11. No abstract available.

18.

Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial.

Mauge L, Mejean A, Fournier L, Pereira H, Etienne-Grimaldi MC, Levionnois E, Caty A, Abadie-Lacourtoisie S, Culine S, Le Moulec S, Linassier C, Théodore C, Ravaud A, Albiges L, Grine A, Tartour E, Milano G, Gille AS, Verkarre V, Helley D, Oudard S; PREINSUT study group.

Clin Cancer Res. 2018 Nov 15;24(22):5534-5542. doi: 10.1158/1078-0432.CCR-18-1045. Epub 2018 Jul 30.

19.

[Impact of neoadjuvant chemotherapy on the peri-operative morbidity of radical cystectomy for muscle invasive bladder cancer].

Michel C, Vordos D, Dumont C, Basset V, Meyer F, Gaudez F, Meria P, Cortesse A, Mongiat-Artus P, de la Taille A, Culine S, Desgrandchamps F, Masson-Lecomte A.

Prog Urol. 2018 Sep;28(10):495-501. doi: 10.1016/j.purol.2018.06.002. Epub 2018 Jul 8. French.

PMID:
29997033
20.

Refining the use of cabazitaxel in metastatic castrate-resistant prostate cancer.

Culine S.

Eur J Cancer. 2018 Jul;97:30-32. doi: 10.1016/j.ejca.2018.04.002. Epub 2018 May 3. No abstract available.

PMID:
29731227
21.

Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer.

Vaughn DJ, Bellmunt J, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Li H, Perini RF, Bajorin DF, de Wit R.

J Clin Oncol. 2018 Jun 1;36(16):1579-1587. doi: 10.1200/JCO.2017.76.9562. Epub 2018 Mar 28.

PMID:
29590008
22.

Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility.

Moktefi A, Pouessel D, Liu J, Sirab N, Maille P, Soyeux P, Bergman CC, Auriault ML, Vordos D, Taille A, Culine S, Allory Y.

Mod Pathol. 2018 Aug;31(8):1270-1281. doi: 10.1038/s41379-018-0023-9. Epub 2018 Feb 21.

23.

Placental Site Trophoblastic Tumor in Nonseminomatous Mixed Germ Cell Tumors of the Testis: a Case Report and Review of the Literature.

Razafimahefa J, Gosset C, Culine S, Mongiat-Artus P, Verine J.

Clin Genitourin Cancer. 2018 Apr;16(2):e349-e354. doi: 10.1016/j.clgc.2017.12.010. Epub 2017 Dec 27. Review. No abstract available.

PMID:
29395947
24.

Choosing a career in oncology: results of a nationwide cross-sectional study.

Faivre JC, Bibault JE, Bellesoeur A, Salleron J, Wack M, Biau J, Cervellera M, Janoray G, Leroy T, Lescut N, Martin V, Molina S, Pichon B, Teyssier C, Thureau S, Mazeron JJ, Roché H, Culine S.

BMC Med Educ. 2018 Jan 15;18(1):15. doi: 10.1186/s12909-018-1117-2.

25.

[Medical treatment of metastatic kidney cancer: targeting the tumor micro-environment].

Gauthier H, Culine S.

Rev Prat. 2018 Jan;68(1):52-55. French.

PMID:
30840388
26.

Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases.

Loriot Y, Pagliaro L, Fléchon A, Mardiak J, Geoffrois L, Kerbrat P, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Malhaire JP, Linassier C, Habibian M, Martin AL, Journeau F, Reckova M, Logothetis C, Laplanche A, Le Teuff G, Culine S, Fizazi K.

Eur J Cancer. 2017 Dec;87:140-146. doi: 10.1016/j.ejca.2017.09.029. Epub 2017 Nov 14.

PMID:
29149760
27.

Customizing Daily Management of Castrate-resistant Prostate Cancer: Waiting for the Next Step.

Culine S.

Eur Urol. 2018 Jul;74(1):24-25. doi: 10.1016/j.eururo.2017.10.016. Epub 2017 Nov 6. No abstract available.

PMID:
29122378
28.

Primary adenocarcinoma of the seminal vesicle.

Terrisse S, Camblor ME, Vérine J, Gauthier H, Mongiat-Artus P, Culine S.

Rare Tumors. 2017 Oct 3;9(3):7074. doi: 10.4081/rt.2017.7074. eCollection 2017 Oct 3. Erratum in: Rare Tumors. 2019 May 03;11:2036361319848842. Comblor, Maria Eugenia [corrected to Camblor, Maria Eugenia].

29.

Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.

Lavaud P, Gravis G, Foulon S, Joly F, Oudard S, Priou F, Latorzeff I, Mourey L, Soulié M, Delva R, Krakowski I, Laguerre B, Théodore C, Ferrero JM, Beuzeboc P, Habibian M, Rolland F, Deplanque G, Pouessel D, Zanetta S, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Tubiana-Mathieu N, Machiels JP, Kouri CE, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Culine S, Boher JM, Tergemina-Clain G, Legoupil C, Fizazi K.

Eur Urol. 2018 May;73(5):696-703. doi: 10.1016/j.eururo.2017.09.022. Epub 2017 Oct 23.

PMID:
29074061
30.

Intratumor heterogeneity of immune checkpoints in primary renal cell cancer: Focus on HLA-G/ILT2/ILT4.

Rouas-Freiss N, LeMaoult J, Verine J, Tronik-Le Roux D, Culine S, Hennequin C, Desgrandchamps F, Carosella ED.

Oncoimmunology. 2017 Jul 5;6(9):e1342023. doi: 10.1080/2162402X.2017.1342023. eCollection 2017.

31.

Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial.

Marino P, Sfumato P, Joly F, Fizazi K, Oudard S, Culine S, Habibian M, Boher JM, Gravis G.

Eur J Cancer. 2017 Oct;84:27-33. doi: 10.1016/j.ejca.2017.07.008. Epub 2017 Aug 4.

PMID:
28780479
32.

Prognostic value of the G8 and modified-G8 screening tools for multidimensional health problems in older patients with cancer.

Martinez-Tapia C, Paillaud E, Liuu E, Tournigand C, Ibrahim R, Fossey-Diaz V, Culine S, Canoui-Poitrine F, Audureau E; ELCAPA Study Group.

Eur J Cancer. 2017 Sep;83:211-219. doi: 10.1016/j.ejca.2017.06.027. Epub 2017 Jul 24.

PMID:
28750273
33.

Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study.

Noize P, Grelaud A, Bay JO, Chevreau C, Gross-Goupil M, Culine S, Ferrière JM, Moulin F, Robinson P, Balestra A, Lamarque S, Bernard MA, Lassalle R, Rouyer M, Droz-Perroteau C, Moore N, Fourrier-Réglat A, Ravaud A.

Pharmacoepidemiol Drug Saf. 2017 Dec;26(12):1561-1569. doi: 10.1002/pds.4228. Epub 2017 Jun 1.

PMID:
28573786
34.

Les traitements combinés dans les formes à haut risque évolutif du cancer de la prostate (localisé ou non).

Monnier L, Culine S, Cormier L.

Presse Med. 2017 Oct;46(10):940-947. doi: 10.1016/j.lpm.2017.03.007. Epub 2017 May 23. French.

PMID:
28549631
35.

Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.

Colomba E, Le Teuff G, Eisen T, Stewart GD, Fife K, Larkin J, Biondo A, Pickering L, Srinivasan A, Boyle H, Derosa L, Sternberg CN, Recine F, Ralph C, Saldana C, Barthélémy P, Bernhard JC, Gurney H, Verhoest G, Vauleon E, Bigot P, Berger J, Pfister C, Gravis G, Rodier JM, Culine S, Caty A, Rolland F, Priou F, Escudier B, Albiges L.

Eur J Cancer. 2017 Jul;80:55-62. doi: 10.1016/j.ejca.2017.03.011. Epub 2017 May 23.

PMID:
28549248
36.

Posterior reversible encephalopathy syndrome with colitis in a patient treated with panitumumab.

Blaye C, Buy X, Gross-Goupil M, Vincent D, Jamet C, Sargos P, Culine S, Roubaud G.

Ther Adv Drug Saf. 2017 Apr;8(4):133-136. doi: 10.1177/2042098616682720. Epub 2017 Jan 16. No abstract available.

37.

First-line management of metastatic castrate-resistant prostate cancer patients: Audit of real-life practices.

Turpin A, Pasquier D, Massard C, Berdah JF, Culine S, Penel N.

Bull Cancer. 2017 Jun;104(6):552-558. doi: 10.1016/j.bulcan.2017.02.002. Epub 2017 Apr 5.

PMID:
28390646
38.

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF; KEYNOTE-045 Investigators.

N Engl J Med. 2017 Mar 16;376(11):1015-1026. doi: 10.1056/NEJMoa1613683. Epub 2017 Feb 17.

39.

Evaluation of the Theoretical Teaching of Postgraduate Radiation Oncology Medical Residents in France: a Cross-Sectional Study.

Faivre JC, Bibault JE, Leroy T, Agopiantz M, Salleron J, Wack M, Janoray G, Roché H, Culine S, Rivera S.

J Cancer Educ. 2018 Apr;33(2):383-390. doi: 10.1007/s13187-017-1170-2.

PMID:
28138918
40.

Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Metastatic Urothelial Carcinoma Patients Treated With First-line Chemotherapy: A Large Multicenter Study.

Auvray M, Elaidi R, Ozguroglu M, Guven S, Gauthier H, Culine S, Caty A, Dujardin C, Auclin E, Thibaut C, Combe P, Tartour E, Oudard S.

Clin Genitourin Cancer. 2017 Jun;15(3):e469-e476. doi: 10.1016/j.clgc.2016.10.013. Epub 2016 Nov 16.

PMID:
27964892
41.

Metastatic Renal Cell Carcinoma in a Renal Allograft: A Sustained Complete Remission After Stimulated Rejection.

Champion L, Culine S, Desgranchamps F, Benali K, Verine J, Daugas E.

Am J Transplant. 2017 Apr;17(4):1125-1128. doi: 10.1111/ajt.14151. Epub 2017 Jan 13.

42.

Early chemotherapy discontinuation and mortality in older patients with metastatic bladder cancer: The AGEVIM multicenter cohort study.

Laurent M, Brureau L, Demery ME, Fléchon A, Thuaut AL, Carvahlo-Verlinde M, Bastuji-Garin S, Paillaud E, Canoui-Poitrine F, Culine S.

Urol Oncol. 2017 Jan;35(1):34.e9-34.e16. doi: 10.1016/j.urolonc.2016.08.003. Epub 2016 Oct 6.

PMID:
27720631
43.

To Treat or Not to Treat Metastatic Cancer Patients with Poor Performance Status: a Prospective Experience.

Kullmann T, Gauthier H, Serrate C, Pouessel D, le Maignan C, Misset JL, Culine S.

Pathol Oncol Res. 2017 Jan;23(1):139-144. doi: 10.1007/s12253-016-0111-4. Epub 2016 Sep 7.

PMID:
27605003
44.

A Statistical Approach to Determine the Optimal Duration of Post-Treatment Follow-Up: Application to Metastatic Nonseminomatous Germ Cell Tumors.

Somda SM, Culine S, Chevreau C, Fizazi K, Leconte E, Kramar A, Filleron T.

Clin Genitourin Cancer. 2017 Apr;15(2):230-236. doi: 10.1016/j.clgc.2016.07.023. Epub 2016 Aug 8.

PMID:
27594552
45.

Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a French Multicenter, Contemporary Cohort.

Pouessel D, Bastuji-Garin S, Houédé N, Vordos D, Loriot Y, Chevreau C, Sevin E, Beuzeboc P, Taille A, Le Thuaut A, Allory Y, Culine S.

Clin Genitourin Cancer. 2017 Feb;15(1):e45-e52. doi: 10.1016/j.clgc.2016.07.012. Epub 2016 Jul 21.

PMID:
27554584
46.

Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumors.

de la Motte Rouge T, Pautier P, Genestie C, Rey A, Gouy S, Leary A, Haie-Meder C, Kerbrat P, Culine S, Fizazi K, Lhommé C.

Gynecol Oncol. 2016 Sep;142(3):452-7. doi: 10.1016/j.ygyno.2016.07.005. Epub 2016 Jul 8.

PMID:
27401840
47.

Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.

Pouessel D, Neuzillet Y, Mertens LS, van der Heijden MS, de Jong J, Sanders J, Peters D, Leroy K, Manceau A, Maille P, Soyeux P, Moktefi A, Semprez F, Vordos D, de la Taille A, Hurst CD, Tomlinson DC, Harnden P, Bostrom PJ, Mirtti T, Horenblas S, Loriot Y, Houédé N, Chevreau C, Beuzeboc P, Shariat SF, Sagalowsky AI, Ashfaq R, Burger M, Jewett MA, Zlotta AR, Broeks A, Bapat B, Knowles MA, Lotan Y, van der Kwast TH, Culine S, Allory Y, van Rhijn BW.

Ann Oncol. 2016 Jul;27(7):1311-6. doi: 10.1093/annonc/mdw170. Epub 2016 Apr 18.

48.

[Castration modalities in prostate cancer: Are they all equal?].

Ploussard G, Bruyère F, Culine S, de La Taille A, Hennequin C, Oudard S, Pfister C, Ravery V, Salomon L.

Prog Urol. 2016 Apr;26(5):319-28. doi: 10.1016/j.purol.2016.02.010. Epub 2016 Mar 23. Review. French.

PMID:
27017327
49.

[Effective palliative chemotherapy in a patient with collecting duct carcinoma of a unilateral kidney associated with anuria. Case report].

Kullmann T, Pintér T, Szepesvári Z, Kránitz N, Culine S.

Orv Hetil. 2016 Mar 13;157(11):436-9. doi: 10.1556/650.2016.30387. Hungarian.

PMID:
26947093
50.

Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?

Pouessel D, Chevret S, Rolland F, Gravis G, Geoffrois L, Roubaud G, Terrisse S, Boyle H, Chevreau C, Dauba J, Moriceau G, Alexandre I, Deplanque G, Chapelle A, Vauleon E, Colau A, Audenet F, Grellety T, Culine S.

Eur J Cancer. 2016 Feb;54:69-74. doi: 10.1016/j.ejca.2015.11.017. Epub 2015 Dec 25.

PMID:
26724422

Supplemental Content

Loading ...
Support Center